openPR Logo
Press release

RAS-Q™ technology receives funding from German Federal Ministry for Education and Research (BMBF)

10-17-2017 01:16 PM CET | Health & Medicine

Press release from: enmodes GmbH

Aachen, October 16, 2017

On Thursday, 09/28/2017, the Aachen (Germany) based enmodes GmbH has received a 1.65 million EUR grant from the German Federal Ministry for Education and Research (BMBF, https://www.bmbf.de/en/index.html). The funds are made available to enmodes jointly with the Lung Clinic Köln-Merheim / University Hospital Witten/Herdecke, and will be utilized to conduct further research into the RAS-Q™ technology (http://www.ras-q.com/), aiming to develop a portable long-term lung support system for the treatment of patients suffering from Chronic Obstructive Pulmonary Disease (COPD). The portable device will for the first time enable lung support in a manner that allows improved resilience and quality of life without respiratory distress.

“Grant givers showed interest in our developments very early on”, recaps Prof. Dr. Tim Kaufmann, CEO and co-founder of enmodes, “in early 2016, just one year after the initial idea for RAS-Q™, we received a first research grant to fund an improved prototype and conduct intensive trials. At the time it was handed out through the Central Innovation Program Mittelstand (ZIM/BMWi). A year later we were able to join the European Horizon 2020 program ‘EIT Health’. Receiving yet another grant at this stage is a very positive signal, and encourages us to bring the RAS-Q™ technology to market maturity and help millions of COPD patients.”

Current projections from the World Health Organization (WHO) indicate that more than 65 million people worldwide suffer from COPD; and is considered to be the fourth most common cause of death in adults (http://www.who.int/mediacentre/factsheets/fs315/en/).

RAS-Q™ will still take a few years until ready for wide-spread market introduction. But Prof. Karagiannidis (Mr.), head of the ECMO Center of the Lung Clinic Köln-Merheim, is certain: “Such a technology can be an immense progress in the therapy of advanced COPD, which is currently only treated with permanent respiration devices that severely impact the quality of life.”

Approving the grant also pursues hands-on economic benefits: Currently, the treatment of a single COPD patient in Germany costs about 25,000 EUR - per month. Using the RAS-Q™ technology not only the long-time prognosis and quality of life of the patients can be improved, but also these cost can be reduced to a fraction.

The researchers are confident to attain the ‘first in man’ trial in the second half of 2020. Afterwards, the product launch and thereby long awaited relief for the patients is within reach.

enmodes GmbH provides design and engineering services to medical device companies with a major focus on validated computational analyses and optimizations.

We offer wide range of assistance and consulting for translational biomedical developments from small research projects to complex ventures based on our clients’ requirements. It is our ambition to create novel approaches and improve existing technology to address current needs and challenges in healthcare.

Together with our partners from healthcare, academia and industry, we lead, guide, or support novel developments from first idea to clinical application.
It is our belief that, with precision, dedication, effort and a spark of ingenuity, we can help our customers shape the future of biomedical device technology.

Christian Wischnewski
wischnewski@enmodes.de

Wilhelmstraße 38
52070 Aachen
Germany

Phone: +49(0)-241-412-510-71

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release RAS-Q™ technology receives funding from German Federal Ministry for Education and Research (BMBF) here

News-ID: 776654 • Views: 541

More Releases for COPD

COPD Therapeutics Global Market Research Report 2019
COPD Therapeutics Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/copd-therapeutics-market/80858 The report firstly introduced the COPD Therapeutics basics: definitions, classifications, applications and market
Asthma and COPD Drugs Market worth $50,359 Million by 2022
"The key players of the Global COPD and asthma drugs market are employing novel concepts and ideas to improve, manage and control asthma & COPD, and also enhance their profitability so as to gain a competitive edge over the other market players. Seretide/Advair, Symbicort, and Singular were leading brands and accounted for around one-fourth share in world COPD and asthma drugs market." Global Asthma and COPD Drugs Market was valued at
Alarming Prevalence of COPD to Propel Oxygen Therapy Devices Market
"Oxygen therapy equipment market driven by increasing urbanization and rising levels of air pollution." An intelligence report on the global oxygen therapy equipment market has been added to the burgeoning portfolio of MarketResearchReports.biz. Titled, “Global Oxygen Therapy Equipment Market - Analysis By Product, Portability, Application, Region, Country: Opportunities and Forecast (2017- 2022) - By Product (Oxygen Concentrators, Liquid Oxygen Devices and Oxygen Cylinders), By Portability (Stationary, Portable Devices), By Application (COPD,
Asthma and COPD Drugs Market | Key Opportunities And Forecast 2024
The top five companies in the U.S. and China Asthma And Copd Drugs Market accounted for just under 64.0% in 2015, hinting at not just the consolidated nature of this industry but also at the immense competition among players. GlaxoSmithKline plc, Astrazeneca plc, Boehringer Ingelheim, Merck & Co. Inc., and Novartis AG currently enjoy the leading spots in the asthma and COPD drugs market. According to Transparency Market Research, the opportunity
Global COPD and Asthma Devices Market Size
According to a new report, Global COPD and Asthma Devices Market, published by KBV Research, The Global COPD and Asthma Devices Market attained a market size of $ 27,465.1 Million in 2015 and is expected to reach $ 39,051.4 Million by 2022 growing at a CAGR of 5.2 % CAGR during 2016 – 2022. The Asia Pacific market dominated the Global COPD and Asthma Devices Market in 2015 and would
COPD Drug Market Opportunity & Clinical Pipeline Analysis
Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the